PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Phase 2 Terminated
146 enrolled
CARTIFAN-1
Phase 2 Terminated
123 enrolled
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
23 enrolled
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Phase 2 Terminated
24 enrolled 8 charts
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Phase 2 Terminated
17 enrolled 9 charts
PROACT
Phase 2 Terminated
49 enrolled 12 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Phase 2 Terminated
4 enrolled 8 charts
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
36 enrolled 17 charts
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Phase 2 Terminated
88 enrolled 21 charts
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Phase 2 Terminated
15 enrolled 12 charts
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Phase 2 Terminated
1 enrolled 14 charts
DarPAL
Phase 2 Terminated
27 enrolled
IFM2014-01
Phase 2 Terminated
26 enrolled
EMBRACE
Phase 2 Terminated
1 enrolled 5 charts
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
Phase 2 Terminated
3 enrolled 5 charts
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Phase 2 Terminated
13 enrolled 9 charts
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Phase 2 Terminated
17 enrolled
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
Phase 2 Terminated
5 enrolled 12 charts
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Phase 2 Terminated
8 enrolled 8 charts
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
Phase 2 Terminated
9 enrolled 9 charts
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Phase 2 Terminated
45 enrolled
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Phase 2 Terminated
45 enrolled
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
Phase 2 Terminated
19 enrolled
ClaSPd
Phase 2 Terminated
4 enrolled 9 charts
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Phase 2 Terminated
1 enrolled 9 charts
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Phase 2 Terminated
12 enrolled 10 charts
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
Phase 2 Terminated
2 enrolled 6 charts
CART-19 Post-ASCT for Multiple Myeloma
Phase 2 Terminated
6 enrolled 7 charts
Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
Phase 2 Terminated
5 enrolled 8 charts
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
Phase 2 Terminated
27 enrolled 13 charts
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
Phase 2 Terminated
18 enrolled 11 charts
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Terminated
46 enrolled 18 charts
A Phase II Study of BI-505 in Smoldering Multiple Myeloma
Phase 2 Terminated
4 enrolled
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
7 enrolled 5 charts
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Terminated
9 enrolled 12 charts
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
Phase 2 Terminated
6 enrolled 17 charts
PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
Phase 2 Terminated
6 enrolled
Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma
Phase 2 Terminated
10 enrolled
Combination Study for High Risk Multiple Myeloma Patients
Phase 2 Terminated
13 enrolled
Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
1 enrolled
RISE-M
Phase 2 Terminated
6 enrolled 11 charts
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
Phase 2 Terminated
38 enrolled 13 charts
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
Phase 2 Terminated
20 enrolled 7 charts
OptiPOM
Phase 2 Terminated
34 enrolled
Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma
Phase 2 Terminated
4 enrolled 12 charts
Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
Phase 2 Terminated
60 enrolled
AntiCD-66
Phase 2 Terminated
25 enrolled
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Phase 2 Terminated
9 enrolled 6 charts